AI Insight
This commentary discusses the interpretation of negative results from studies examining faecal microbiota transplantation (FMT) as a treatment for irritable bowel syndrome (IBS). IBS is a chronic gastrointestinal disorder characterized by abdominal pain and altered bowel habits, with complex pathophysiology involving gut-brain axis dysregulation. The article addresses the challenge that despite improved understanding of IBS mechanisms, effective disease-modifying treatments remain limited and largely symptom-focused.
Why it matters
Understanding why FMT trials show negative results in IBS is crucial for developing more targeted microbiome-based therapies and avoiding premature abandonment of potentially useful treatment approaches. This analysis helps researchers refine patient selection criteria and study design for future microbiome intervention studies in functional gastrointestinal disorders.
Understand the Science
Irritable bowel syndrome (IBS) is a chronic disorder characterised by abdominal pain or discomfort and altered bowel habits, arising from multiple pathophysiological mechanisms involving dysregulation of the gut–brain axis. Despite advances in understanding IBS pathogenesis, treatment remains largely empirical and symptom-directed, and there are few disease-modifying therapies.1,2